KCA
AXSM icon

KVP Capital Advisors’s Axsome Therapeutics AXSM Stock Holding History

KVP Capital Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.94M Sell
12,000
-24,200
-67% -$5.25M 2.16% 18
2026
Q1 		$6.12M Hold
36,200
– – 4.57% 4
2025
Q4 		$6.61M Buy
+36,200
New +$5.05M 6.4% 3

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

KVP Capital Advisors's AXSM Position: Q2 2026 in Review

KVP Capital Advisors reduced its Axsome Therapeutics (AXSM) stake by 67% in Q2 2026, selling an estimated $5.25M and leaving 12,000 shares worth $2.94M. The position accounts for 2.16% of the portfolio, ranked #18.

KVP Capital Advisors first reported a position in AXSM in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.61M in Q4 2025. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • KVP Capital Advisors held 12,000 shares of Axsome Therapeutics worth $2.94M as of Q2 2026.
  • KVP Capital Advisors sold 24,200 Axsome Therapeutics shares in Q2 2026, an estimated $5.25M.
  • Axsome Therapeutics made up 2.16% of KVP Capital Advisors's portfolio in Q2 2026, its #18 holding.
  • KVP Capital Advisors first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • KVP Capital Advisors's Axsome Therapeutics position peaked at $6.61M in Q4 2025.
  • 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on KVP Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.